Galectin Therapeutics Inc (FRA:PHPN)
€ 2.38 0.04 (1.71%) Market Cap: 151.00 Mil Enterprise Value: 213.71 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 38/100

Galectin Therapeutics Inc at H.C. Wainwright BioConnect Investor Conference Transcript

May 02, 2023 / 02:30PM GMT
Release Date Price: €1.51 (-2.58%)
Ed Arce
H. C. Wainwright & Co., LLC - Analyst

Great. Well, we'll get started. Our next presenting company is Galectin Therapeutics. And joining us is the President and CEO, Joel Lewis; as well as Pol Boudes, the Chief Commercial Officer -- sorry, Medical Officer.

Joel Lewis
Galectin Therapeutics Inc. - CEO & President

He can be the Chief Commercial Officer too.

Ed Arce
H. C. Wainwright & Co., LLC - Analyst

Good, good. Welcome, both of you.

Joel Lewis
Galectin Therapeutics Inc. - CEO & President

Thank you.

Pol Boudes
Galectin Therapeutics Inc. - Chief Medical Officer

Welcome.

Ed Arce
H. C. Wainwright & Co., LLC - Analyst

So I wanted to start if you could just briefly introduce the company and its strategy.

Joel Lewis
Galectin Therapeutics Inc. - CEO & President

Sure. First of all, thank you to Ed and H.C.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot